The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as a first-line treatment. This evidence concerns the gene AFP and hepatocellular carcinoma.